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A Reminder of Methylene 
Blue’s Effectiveness
in Treating Vasoplegic Syndrome 
after On-Pump Cardiac Surgery
The inflammatory response induced by cardiopulmonary bypass decreases vascular tone, 
which in turn can lead to vasoplegic syndrome. Indeed the hypotension consequent to 
on-pump cardiac surgery often necessitates vasopressor and intravenous fluid support. 
Methylene blue counteracts vasoplegic syndrome by inhibiting the formation of nitric oxide.
We report the use of methylene blue in a 75-year-old man who developed vasoplegic 
syndrome after cardiac surgery. After the administration of methylene blue, his hypotension 
improved to the extent that he could be weaned from vasopressors. The use of methylene 
blue should be considered in patients who develop hypotension refractory to standard treat-
ment after cardiac surgery. (Tex Heart Inst J 2015;42(5):491-4)
Vasoplegic syndrome (VS) is a condition characterized by hypotension (mean arterial pressure, <50 mmHg), increased cardiac index (CI) (>2.5 L/min/m2), low systemic vascular resistance (<800 dynes·s/cm5), normal or increased fill-
ing pressures, and increased vasopressor and fluid requirements. This phenomenon 
occurs in approximately 5% of patients who undergo cardiac surgery.1 Although the 
mechanism of VS is largely unknown, study results suggest a multifactorial cause 
consisting of hemodilution, baroreceptor ref lexes, complement activation, and an 
inflammatory response that results in the release of nitric oxide and in subsequent 
vasodilation.2
 Methylene blue (MB), a nitric oxide synthase inhibitor, has been shown to be a safe 
and effective therapeutic option in patients with hypotension refractory to vasopres-
sors and fluids after on-pump cardiac surgery.3,4 The following case report discusses 
the use of MB in a patient who remained hypotensive after aortic valve replacement 
and tricuspid valve repair, despite f luid resuscitation and standard vasopressor infu-
sions.
Case Report
In September 2013, a 75-year-old black man with a history of coronary artery disease, 
congestive heart failure, end-stage renal disease, and hypertension presented at our 
hospital with shortness of breath and hypotension that had begun during dialysis. 
He was stabilized with dobutamine and fluids and was subsequently admitted for 
further evaluation.
 A transthoracic echocardiogram revealed severe aortic stenosis with a valve area 
of 0.7 cm2, severe tricuspid regurgitation, moderate pulmonary hypertension with a 
peak right ventricular systolic pressure of 57 mmHg, and a left ventricular ejection 
fraction of 0.35 to 0.40. Coronary angiograms showed mild coronary artery disease. 
The patient’s condition worsened, and he was transferred to the intensive care unit 
on high doses of inotropic agents. His pulmonary artery pressure was 60/30 mmHg, 
and his CI was 2.1 L/min/m2 on 25 µg/kg/min of dobutamine.
 He was taken to the operating room for replacement of the aortic valve with a 
23-mm Carpentier-Edwards Perimount® Magna® pericardial valve and for repair of 
the tricuspid valve with a 32-mm Carpentier-Edwards Physio II® annuloplasty ring 
(both Edwards Lifesciences LLC; Irvine, Calif ). An intraoperative transesophageal 
echocardiogram showed normal left ventricular function. Total cross-clamp and car-
diopulmonary bypass (CPB) times were 115 and 193 min, respectively. The patient’s 
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epinephrine, 0.25 µg/kg/min of norepinephrine, 0.04 
U/min of vasopressin, and 0.3 µg/kg/min of milrinone. 
Hemodynamic measurements immediately after sur-
gery revealed a CI of 3.47 L/min/m2 and a systemic 
vascular resistance (SVR) of 425 dynes·s/cm5. The 
pulmonary artery diastolic pressure (PAD) was 19 
mmHg. Norepinephrine was increased gradually over 
the next 6 hours to 0.4 µg/kg/min, but the patient’s 
MAP reached only 53 mmHg. His CI decreased to 2.9 
L/min/m2 and his SVR increased to 625 dynes·s/cm5. 
The PAD remained 19 mmHg. In addition to admin-
istering the high dose of norepinephrine, we aggressively 
pursued and accomplished volume resuscitation, with 
no improvement in MAP.
 Because the patient’s blood pressure and SVR did not 
respond to high doses of vasopressors and fluids, we ad-
ministered a 50-mg dose of MB. Over the next 3 hours, 
his MAP increased to 74 mmHg, SVR increased to 825 
dynes·s/cm5, and CI decreased to 2.4 L/min/m2. The 
PAD was not affected by MB administration. Norepi-
nephrine was tapered to 0.24 µg/kg/min, epinephrine 
was decreased to 0.08 µg/kg/min, and the patient re-
mained normotensive. Figure 1 shows the postoperative 
variations in MAP and norepinephrine infusion. The 
cortisol level, which was checked to rule out adrenal 
insufficiency, was normal (35.6 µg/dL). About a month 
later, the patient died of noncardiac causes.
Discussion
Vasoplegic syndrome is a potentially fatal condition 
after cardiac surgery; Gomes and colleagues5 found 
an increased morbidity and mortality rate in patients 
who developed VS that persisted for 36 to 48 hours 
postoperatively. Cardiopulmonary bypass elicits a severe 
inflammatory response that releases such substances as 
histamine, cytokines, and interleukins. These substanc-
es initiate the conversion of arginine to nitric oxide, via 
nitric oxide synthase. Nitric oxide then up-regulates the 
guanylate cyclase enzyme, which in turn increases in-
tracellular cyclic guanosine monophosphate (cGMP)—
resulting in systemic vasodilation and hypotension.1,6,7 
Methylene blue has been shown to counteract this va-
sodilation by inhibiting nitric oxide synthase3 (Fig. 2).
 Risk factors associated with the development of VS 
have been identif ied. Investigators have found an as-
sociation between the development of VS after cardiac 
surgery and the preoperative use of heparin, angioten-
sin-converting enzyme (ACE) inhibitors, and calcium 
channel blockers.7,8 Our patient was not administered 
any of these medications preoperatively. The type of 
surgery being performed has also been shown to be an 
independent risk factor for the development of vasople-
gia. Specif ically, valve procedures increase the risk of 
developing VS, in comparison with coronary artery 
bypass grafting.1 In 2009, M.A. Levin and colleagues9 
showed a correlation between a decrease in MAP im-
mediately after CPB initiation and the development of 
VS. The decrease in MAP was quantified by calculating 
the area above the MAP curve. A clinically significant 
area above the curve was defined as a decrease in MAP 
of >20% within the first 5 minutes of cardiopulmonary 
bypass, beginning at baseline (before CPB initiation). 
Patients who experienced a significant decline in intra-
operative MAP had a 23% chance of developing post-
operative VS versus a 16.9% chance in those who did 
not have a significant decline in intraoperative MAP. 
Other risk factors for postoperative development of VS 
in Levin’s study9 included the old additive EuroScore 
(the method used before 2011 to calculate predicted 
operative mortality rates in patients undergoing heart 
surgery), the procedure type, the length of CPB, the 
pre- and post-CPB hematocrits, the core temperature 
on CPB, and preoperative ACE-inhibitor or β-blocker 
use.
 Because of its effect on the nitric oxide pathway, MB 
is able to improve hemodynamic status. In a study con-
ducted by Leyh and colleagues,4 MB administration 
signif icantly increased SVR and MAP in 92.4% of 
patients within 12 hours after its infusion. Furthermore, 
Fig. 1  Graphs show A) mean arterial pressure variations and  
B) the norepinephrine infusion rate, versus time after cardiac 
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norepinephrine requirements decreased from 0.5 to 0.2 
µg/kg/m2 just 6 hours after the administration of MB. 
However, Leyh’s study was limited by small sample size 
and lack of randomization. Ozal and coworkers10 vali-
dated the benefit of MB in their randomized-control 
trial. One hundred patients who were scheduled to 
undergo coronary artery bypass grafting and were at 
high risk of developing vasoplegic syndrome (because of 
their preoperative use of ACE inhibitors, calcium chan-
nel blockers, or heparin) were randomized to receive 
either MB or placebo preoperatively. The prevalence of 
vasoplegia in the treatment and control groups was 0 
and 26%, respectively. Those who received MB had 
a signif icantly higher postoperative SVR and MAP, 
needed fewer norepinephrine and crystalloid infusions, 
and underwent a significantly shorter mean length of 
stay in intensive care units.
 In 2004, 56 patients who developed VS after cardiac 
surgery were randomized to receive a single dose (1.5 
mg/kg) of MB or placebo.3 The mortality rate in the 
placebo group was 21.4%, yet there were no deaths in 
the group that received MB. The rates of renal failure, 
respiratory failure, and sepsis in the placebo group were 
14.3%, 14.3%, and 25%, respectively, whereas these 
particular comorbidities did not occur among the pa-
tients treated with MB.
 Methylene blue is the primary treatment for methe-
moglobinemia and is sometimes used to treat cyanide 
poisoning. More recently it has been shown to be ef-
fective in the treatment of vasoplegia related to sepsis11 
and vasoplegia after severe protamine reactions.12 In ad-
dition, MB has been shown to decrease hemodialysis-
related hypotension13 and hypotension that results from 
chronic ACE-inhibitor use.7
 Common adverse effects associated with MB are 
minimal and include greenish-blue–colored urine and 
decreased (misleadingly so) pulse oximetry readings. 
Other notable side effects include cardiac arrhythmias, 
decreased cardiac output, increased pulmonary vascular 
pressure, abdominal pain, nausea, and headache; how-
ever, these are less frequent.4,7
 The dosing and delivery method of MB administra-
tion is debatable. Methylene blue is available as a solution 
(10 mg/mL), and is typically administered to patients 
who develop VS after cardiac surgery as a 1- to 2-mg/kg 
bolus.3,4,7 A continuous infusion may be used in patients 
who do not respond to a single bolus.7 Our patient’s 
weight was 61 kg; a 50-mg dose of MB sufficiently im-
proved hemodynamic levels, so we did not resort to a 
higher dose or continuous infusion. Because MB is not 
easily titratable and carries the risk of misleading pulse 
oximetry readings, we typically elect to use standard 
first-line treatments such as norepinephrine and vaso-
pressin. If these medications fail, we use MB.
 In conclusion, the goal of this case study is not to 
present novel findings; rather, it is to remind clinicians 
of the usefulness of MB in patients who develop va-
soplegia. It is used in approximately 5% of our own sur-
gical population and has proved to be a very successful 
tool in combating refractory hypotension. Vasoplegic 
syndrome seen after cardiac surgery is associated with 
high morbidity and mortality rates. Predictors of post-
operative VS have been identif ied, and patients with 
those risk factors might well benef it from treatment 
with MB.
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Fig. 2  Diagram shows the mechanism of action of methylene blue in the nitric oxide pathway. 
 
cGMP = cyclic guanosine monophosphate; NO = nitric oxide
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